Cancer is the second leading cause of death worldwide, and sadly, one in six people die from this disease.

Radiotherapy is used in over 50% of cancer patients. However, it has major drawbacks: it damages healthy tissue—leading to severe side effects—requires multiple sessions, and has limited effectiveness against deep or resistant tumors.

There are alternative approaches known as radiosensitizers, which aim to enhance the effects of radiation therapy. However, they still face significant limitations: low efficiency, lack of specificity, or inability to reach all tumors. These weaknesses limit their clinical application and highlight the urgent need for new strategies.

We have developed a technology that revolutionizes radiotherapy by increasing its effectiveness and reducing its adverse effects, especially reaching hard-to-access tumors, without the need for new equipment.

Our solution, administered intravenously prior to radiotherapy, acts as a local amplifier of radiation. It is based on bismuth sulfide nanoparticles, coated with a biocompatible polymer and functionalized to efficiently travel through the bloodstream, selectively increasing their concentration in tumors by 20%.

Under standard conditions, a single session of radiotherapy eliminates approximately 5% of tumor cells. With the incorporation of NanoProX, this effectiveness is significantly enhanced, reaching up to 40%.